Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grunenthal GmbH
Kyowa Kirin To Offload Selected Mature Portfolio To Grünenthal
The Japanese and German firms agree to establish a joint company to handle 13 mature brands from Kyowa Kirin's portfolio, mainly focused on pain management and including Abstral and PecFent. Grünenthal will own 51% and plans to fully buy out the operation in early 2026.
Shionogi Moves To Build Pipeline Amid Progress Challenges
Shionogi unveiled its latest pipeline update, including a focus on long-standing key areas such as HIV and COVID-19 and a new obesity candidate, at its recent R&D Day, amid struggles to line up new products for launch over the next few years. The Japanese firm also seems set to seek further in-licencing collaborations.
Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback
Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
- Medical Devices
- Other Names / Subsidiaries
- Adhesys Medical GmbH
- Adhesys Medical Inc.
- Averitas Pharma, Inc.
- Grunenthal GmbH
- Gruenenthal GmbH
- Grunental GmbH
- Inversiones Gruchi S.A.
- Inversiones Gruchi Limitada
- Laboratorios Andrómaco S.A.
- Laboratoires Grunenthal SAS
- Mestex AG
- Thar Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.